Market focus ZebraSci specializes in parenteral combination product testing and packaging inspection, offering end-to-end support from early feasibility to post-market investigations, presenting opportunities to cross-sell verification, validation, and lot release services to current and new clients in biotech and pharma.

Quality leadership With cGMP, FDA registration, ISO 17025 and ISO 13485 compliance, and a robust quality management system, ZebraSci can position itself as a trusted partner for major biologics and small molecule companies seeking reliable CRO/CDMO with stringent quality controls.

Expansion potential Two large facilities with over 30,000 square feet of clean rooms and labs indicate capacity for accelerated testing programs and larger client engagements, enabling upsell to scaled combination product development and concurrent testing projects.

Leadership signal Past leadership addition and decade-long track record in helping clients commercialize over 30 combination products signals stability and growth potential, making ZebraSci a compelling partner for prospective customers seeking proven execution capabilities.

Financial foothold With reported revenue in the 10 to 25 million range and a client base across geographies, ZebraSci offers a mid-market entry point for pharma and biotech firms seeking compliant CRO/CDMO services without engaging at the top-tier price tier.